Atlas Trials

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Clinical trial NCT04558918 · COMPLETED

Trial details

NCT number
NCT04558918
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Start date
2021-01-25
Primary completion
2022-09-26
Enrollment
97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.